Baricitinib news

All news on Baricitinib (also known as Olumiant): plants, production capacities, investments and involved companies.

27 February 2026

Lilly's Olumiant Gains CHMP Nod for Adolescent Alopecia Areata in EU

CHMP backs Olumiant for severe alopecia areata in adolescents, based on Phase 3 study showing 42% achieved 80% scalp hair coverage at 36 weeks. Awaiting European Commission decision.

Who will be producing Baricitinib in the future?

Find out with chemXplore Alpha

Learn more